News from the Scientific Circuit
 Last week in Washington, D.C. our R&D team presented at the 9th International Conference on Fine Particle Magnetism. At this meeting we shared our most recent preclinical experimental results coming from our collaboration with the University of New Mexico focused on targeted tumor detection of Her2+ breast cancer models. This work, along with the programs with our other collaborators, is critical to our efforts to establish a route to first in human testing.
|
|
|
Additionally, on June 1st, Dr. Dale Huber, our collaborator from CINT, made a presentation to the 11th International Conference on the Scientific and Clinical Applications of Magnetic Carriers highlighting the biodistribution properties of our PrecisionMRX® nanoparticles. Several other presentations at the meeting referenced our PrecisionMRX® nanoparticles as the gold standard.
|
|
Seeing is Believing
 Our approach to cancer detection relies on the use of cancer specific antibodies to target the tumor. In our recent pre-clinical studies we have shown that an anti-ERB2 antibody bound to our PrecisionMRX® nanoparticles is able to circulate and bind to Her2+ tumor cells. As pictured here, the nanoparticles initially bind to the cancer cell surface receptors and are then internalized over time. Once bound to the cancer cells, we can use our highly sensitive MRX™ instrument to detect very small tumors.
|
|
|
|
|
|
